Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy
Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.
Pharma & Biotech
Pharma & Biotech
Why Star Therapeutics’ complete VGA039 dataset matters for the future of von Willebrand disease care
See why Star Therapeutics’ complete VGA039 data at ISTH 2026 could reshape von Willebrand disease prophylaxis and Incyte’s strategy.
Features & Analysis
A rare disease policy shift just landed at the WHO. Could it change hemophilia care worldwide?
Find out how the WHO hemophilia resolution could reshape diagnosis, treatment access, prophylaxis and bleeding disorder care worldwide.
Pharma & Biotech
Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
Star Therapeutics won dual FDA designations for VGA039 in von Willebrand disease. Read what it could change, and what still needs proving.
Medical Devices & Diagnostics
LUNA trial 2026: Spark Biomedical tests non-pharmacological device for heavy menstrual bleeding
Spark Biomedical launches LUNA Phase II trial evaluating wearable auricular neurostimulation for heavy menstrual bleeding. What the study design reveals.